NantOmics to Present Data on Using GPS Cancer Quantitative Proteomic Analysis of Class III B-Tubulin (TUBB3) to Predict Survival in Gastric Cancer Patients Randomized to Docetaxel at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

Results to be presented during gastrointestinal (noncolorectal) cancer session at the ASCO 2017 Annual Meeting

CHICAGO--()--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular diagnostics and a member of the NantWorks ecosystem of families, will present findings on how the quantitative proteomic analysis element of GPS cancer test of TUBB3 and TYMP may be predictive in cancer indications such as gastric cancer (GC) when docetaxel or 5-fluorouracil (5-FU) is adjuvant to chemotherapy. This will be presented during the gastrointestinal (noncolorectal) cancer session at the the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, an event bringing together 30,000 oncology professionals from June 2-6, 2017 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #19135 during the event.

“We’re excited to be presenting results that could eventually predict patient survival – especially for a subset of cancer like gastric cancer that expected to see 28,000 new cases this year[1],” said Patrick Soon-Shiong, MD, founder of NantWorks. “Currently there are no predictive biomarkers for chemotherapy that have been validated for clinical use. As such, we’re looking forward to developing this unmet need and exploring how quantitative protoemics can be used to change this.”

Presentation Details

Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3, Abstract #4068


        NantOmics, LLC


Gastrointestinal (Noncolorectal) Cancer Session, Poster #60


June 3, 8:00-11:30 AM CT


Hall A, McCormick Place

Presentation Summary

This study evaluated the relationship between survival and TUBB3 and TYMP proteins quantitated by mass spectrometry in the tumor samples of 247 patients from the Intergroup Trial of Adenocarcinoma of the Stomach (ITACA-S). Patients had been randomized to a docetaxel-containing adjuvant regimen or to monotherapy with fluorouracil and leucovorin (5-FU/LV). The study showed that quantitative proteomic analysis of TUBB3 identified a subset of GC patients who benefitted from the addition of docetaxel to adjuvant chemotherapy. GC patients with TUBB3-expressing tumors had worse outcomes on a docetaxel-containing regimen than on 5-FU/LV and an ongoing study of triple-negative breast cancer patients treated with docetaxel suggests that proteomic TUBB3 may be predictive in other cancer indications. Simultaneously, this GC study also established response thresholds for 5-FU as a single active agent and in combination with docetaxel. Quantitative proteomic measurement of thymidine phosphorylase (TYMP) identified a subset of GC patients who benefited from 5-FU regimen. As a result, the study indicates that personalized chemotherapy based on quantitated TUBB3 and TYMP is promising and warrants broader evaluation.

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantWorks

NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure. The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please visit and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About GPS Cancer™

GPS Cancer™ is a unique, molecular scan available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient's cancer and an assessment of protein pathway function to inform personalized treatment strategies. GPS Cancer scanning is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world's most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit and


Jen Hodson, 562-397-3639


Jen Hodson, 562-397-3639